MedTrace Logo

Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

NCT00139386 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1119

Last updated 2013-04-18

No results posted yet for this study

Summary

Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events.

The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.

Conditions

Interventions

DRUG

Candesartan

Candesartan Cilexetil (4-12 mg per day)

Sponsors & Collaborators

  • The 4C trial bureau

    collaborator UNKNOWN

  • Japan Heart Foundation

    collaborator OTHER

  • Kumamoto University

    lead OTHER

Principal Investigators

  • Hisao Ogawa, MD, PhD · Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2009-04-30
Completion
2012-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139386 on ClinicalTrials.gov